HLA-DR 抗体
Quick Overview for HLA-DR 抗体 (ABIN6939639)
抗原
适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
纯化方法
- Purified by Protein A/G
-
亚型
- IgG1 kappa
-
-
anti-HLA-DR (HLA-DR) antibody (FITC)
HLA-DR 适用: 人 FACS 宿主: 小鼠 Monoclonal MEM-12 FITC
anti-HLA-DR (HLA-DR) antibodyHLA-DR 适用: 人 FACS, WB, IHC, IF, ISt, StM 宿主: 小鼠 Monoclonal SPM289 unconjugated
anti-HLA-DR (HLA-DR) antibodyHLA-DR 适用: 人, 犬, Non-Human Primate FACS, WB, IP, IHC (fro), IHC (p), ICC 宿主: 小鼠 Monoclonal L243 unconjugated
anti-HLA-DR (HLA-DR) antibodyHLA-DR 适用: 人 FACS, WB, IP 宿主: 小鼠 Monoclonal MEM-12 unconjugated
anti-HLA-DR (HLA-DR) antibody (PE)HLA-DR 适用: 人, 犬, Non-Human Primate FACS 宿主: 小鼠 Monoclonal L243 PE
anti-HLA-DR (HLA-DR) antibodyHLA-DR 适用: 人, 犬, Non-Human Primate FACS, WB, IP, IHC (fro), IHC (p), ICC, Func 宿主: 小鼠 Monoclonal L243 unconjugated
anti-HLA-DR (HLA-DR) antibodyHLA-DR 适用: 人 FACS, IP 宿主: 小鼠 Monoclonal HL-39 unconjugated
anti-HLA-DR (HLA-DR) antibody (PerCP)HLA-DR 适用: 人 FACS 宿主: 小鼠 Monoclonal MEM-12 PerCP
anti-HLA-DR (HLA-DR) antibody (APC)HLA-DR 适用: 人 FACS 宿主: 小鼠 Monoclonal MEM-12 APC
anti-HLA-DR (HLA-DR) antibody (PE)HLA-DR 适用: 人 FACS 宿主: 小鼠 Monoclonal MEM-12 PE
-
-
应用备注
-
Positive Control: Raji, Ramos or Daudi whole cell lysates. Spleen, tonsil or liver tissue lysates. Human melanoma, tonsil or lymph node.
Known Application: Flow Cytometry (1-2 μg/million cells), Western Blot (1-2 μg/mL), Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT),(Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.
-
限制
- 仅限研究用
-
-
-
浓度
- 200 μg/mL
-
缓冲液
- 10 mM PBS with 0.05 % BSA & 0.05 % azide.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-80 °C
-
储存方法
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
-
有效期
- 24 months
-
-
- HLA-DR
-
别名
- HLA-DR
-
背景
- Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4+ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in MHC class II/ dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the sub- sequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane anchored heavy chain and a light chain ( -Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.
-
分子量
- 36kDa (alpha chain), 27kDa (beta chain), 63kDa (HLA-DR dimer)
-
基因ID
- 3122
-
UniProt
- P01903
-
途径
- Human Leukocyte Antigen (HLA) in Adaptive Immune Response
抗原
-
